Trial Profile
Ziv-aflibercept in Eyes With Eyes With Retinal Diseases and Poor Vision-phase I
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Central retinal vein occlusion; Vision disorders; Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms ZIV
- 03 Jul 2014 New trial record